knowledge -WSS

knowledge

author：fashion 2025-09-28 21:04:45 - browse：81

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout LOUD podcast, live from the STAT Breakthrough Summit East

hotspot

WSS

Biotech investment managers search for lucrative opportunities

With Wegovy coverage, Medicare patients may face high costs

'Essentially witchcraft:' A former naturopath takes on the field

NIH tests clinical research in primary care with $30 million program

This gene therapy has record $4.25 million price. It's saved children.

Report captures long Covid’s disabling effects and policy challenges

knowledge

knowledge

knowledge

What does generative AI mean for health care? We asked experts

U.K. officials, researchers try to ease path for bespoke genetic treatments

Psychedelics group wrestles with new pharma identity

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Jerome Adams on the need for new antivirals for Covid

Yancopoulos of Regeneron works to expand Dupixent success

Sports medicine is finally prioritizing gender equality

Health care court cases: Humana, Sutter, Novant

23andMe had bad news about my health. I wish a person had delivered it

NIH tests clinical research in primary care with $30 million program

entertainment

Yancopoulos of Regeneron works to expand Dupixent success

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Bring on the sabbaticals for nurses

Health care court cases: Humana, Sutter, Novant

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

5 takeaways from STAT's examination of Zynex Medical

hotspot

hotspot

Wikipedia

explore